Isentress 400mg film-coated tablets
raltegravir
Read this label carefully before starting to take this medicine, as it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
other people even if they have the same symptoms as you, as it may harm them.
even if they are not listed in this label. See section4.
What is Isentress
Isentress contains the active ingredient raltegravir. Isentress is an antiviral medication that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immunodeficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus to enter the body's cells and multiply. Isentress prevents this enzyme from functioning. When used with other medications, Isentress can reduce the amount of HIV in the blood (this is known as its “viral load”) and increase the count of CD4 cells (a type of white blood cell that plays an important role in maintaining a healthy immune system to help fight infection). By reducing the amount of HIV in the blood, it can improve the functioning of the immune system. This means that the body can fight better against the infection.
When to use Isentress
Isentress is used to treat patients who are infected with HIV. Your doctor has prescribed Isentress to help you control the HIV infection you have.
Do not take Isentress:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Isentress.
Remember that Isentress does not cure HIV infection. This means that you may still experience infections or other HIV-related illnesses. You should continue to visit your doctor regularly while taking this medication.
Mental health problems
Inform your doctor if you have a history of depression or mental illness. Depression, including suicidal thoughts and behaviors, has been observed in some patients taking this medication, especially in patients with a previous history of depression or mental illness.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (bone tissue death caused by loss of blood supply to the bone). Factors that may increase the risk of developing this disease include the duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunosuppression, significant weight gain, and others. Signs of osteonecrosis include joint stiffness, pain, and difficulty moving (especially in the hip, knee, and shoulder). If you experience any of these symptoms, visit your doctor.
Liver problems
Inform your doctor, pharmacist, or nurse if you have had liver problems in the past, including hepatitisB or C. Your doctor may evaluate the severity of your liver disease before deciding whether you can take this medication.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, inform your doctor, pharmacist, or nurse immediately. Some patients with advanced HIV infection and a history of opportunistic infections may experience signs and symptoms of inflammation due to previous infections shortly after starting HIV treatment. These symptoms are believed to be due to the improvement of the body's immune response, which allows the body to fight infections that may have been present but not producing obvious symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after starting HIV treatment. These disorders can occur many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and ascending to the trunk of the body, palpitations, tremors, or hyperactivity, inform your doctor immediately to receive necessary treatment.
Muscle problems
Contact your doctor, pharmacist, or nurse immediately if you experience unexplained muscle pain, sensitivity to pressure, or muscle weakness during treatment with this medication.
Skin problems
Contact your doctor immediately if you experience a rash. Severe and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medication.
Other medications and Isentress
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication with or without a prescription.
Isentress may interact with other medications.
Inform your doctor, pharmacist, or nurse if you are taking, have taken recently, or may need to take:
Taking Isentress with food and drinks
See section3.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant or breastfeeding, consult your doctor, pharmacist, or nurse before using any medication.
Driving and operating machinery
Do not operate machinery, drive, or ride a bike if you feel dizzy after taking this medication.
Isentress contains lactose
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Isentress contains sodium
This medication contains less than 1mmol of sodium (23mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medication indicated by your doctor, pharmacist or nurse. In case of doubt, consult your doctor, pharmacist or nurse again. Isentress should be used in combination with other medications for HIV infection.
How muchto take
Adults
The recommended dose is 1tablet (400mg) by mouth twice a day.
Use in children and adolescents
The recommended dose of Isentress is 400mg by mouth twice a day for adolescents and children who weigh at least 25kg,
Do not chew, crush or break the tablets because it may alter the amount of medication in your body. You can take this medication with or without food or drinks.
Isentress is also available in 600mg tablets, chewable tablets and granules for oral suspension.
Do not interchange between the 400mg tablets, 600mg tablets, chewable tablets or granules for oral suspension without consulting your doctor, pharmacist or nurse first.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, consult your doctor.
If you forgot to take Isentress
If you interrupt the treatment with Isentress
It is very important that you take Isentress exactly as your doctor has told you.Do not change the dose or stop taking this medication without consulting your doctor, pharmacist or nurse first.Do not stop taking it, because:
If you have any other doubts about the use of this medication, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects–these are rare (may affect up to 1 in 100people)
Seek medical attention immediately if you notice any of the following side effects:
Seek medical attention immediately if you notice any of the side effects mentioned above.
Frequent:the following side effects may affect up to 1 in 10people
Rare: the following side effects may affect up to 1 in 100people
Other side effects in children and adolescents
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet.You can also report them directly through thenational notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Isentress
The active ingredient is raltegravir. Each film-coated tablet contains 400 mg of raltegravir (potassium).
The other components are: lactose monohydrate, microcrystalline cellulose, anhydrous dibasic calcium phosphate, hypromellose 2208, poloxamer 407, sodium stearate, and magnesium stearate. Additionally, the coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, red iron oxide, and black iron oxide.
Appearance of the product and contents of the package
The film-coated tablet of 400 mg is oval in shape, pink in color, and has the inscription "227" engraved on one side.
There are two package sizes available: a bottle of 60 tablets and a multiple-pack containing three bottles of 60 tablets each. The bottle contains a desiccant.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For more information about this medication, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien MSD Belgium Tel/Tel: +32(0)27766211 | Lietuva UAB Merck Sharp & Dohme Tel.: +370 5 278 02 47 |
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 | Ceská republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 |
Danmark MSD Danmark ApS Tlf: +45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) |
Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Eesti Merck Sharp & Dohme OÜ Tel.: +372 6144 200 | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 |
Ελλάδα MSD Α.Φ.Β.Ε.Ε. Τηλ: + 30 210 98 97 300 | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Polska MSD Polska Sp.z o.o. Tel.: +48 22 549 51 00 |
France MSD France Tél: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | România Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204201 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o. Tel.: +421 2 58282010 |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804 650 |
Κύπρος Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700) | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvija SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 | United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 |
Last review date of this leaflet: {MM/AAAA}
For detailed information about this medication, please visit the European Medicines Agency website: http://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.